The FDA just slapped Patrick Soon-Shiong’s ImmunityBio with a warning letter over "misleading" claims for its bladder cancer drug, Anktiva. The media is feasting on the carcass of a billionaire’s reputation, painting a picture of a rogue scientist playing fast and loose with the truth. They are missing the point. The real scandal isn't that a biotech founder used optimistic language; it’s that we have built a regulatory apparatus that prioritizes linguistic purity over patient survival.
If you read the standard reporting, you’ll hear that ImmunityBio overstepped by suggesting Anktiva is a "breakthrough" or that its efficacy data is "unprecedented." The FDA’s grievance is essentially a high-stakes grammar check. They aren't arguing the drug doesn't work. They are arguing about the adjectives used to describe how well it works. While bureaucrats at the Office of Prescription Drug Promotion (OPDP) spend their billable hours parsing press releases, patients with non-muscle invasive bladder cancer (NMIBC) are still facing radical cystectomies—the surgical removal of their bladders—because the "approved" gold standards are failing them.
The Myth of the Objective Efficacy Metric
The FDA loves the "Complete Response" (CR) rate. It’s their holy grail. In the trial that got Anktiva approved, the drug showed a 62% CR rate. To the layperson, that sounds like a win. To the FDA’s marketing police, any attempt to contextualize that number against historical failures is "misleading" because cross-trial comparisons are the original sin of clinical reporting.
Here is the inconvenient truth: every doctor on the front lines makes cross-trial comparisons every single day. If I’m a clinician, I don't care if the FDA thinks it’s "unscientific" to compare Anktiva’s 62% to the dismal historical rates of Merck’s TICE BCG. I care that my patient gets to keep their bladder. By gagging companies from discussing the relative merits of new therapies, the FDA isn't "protecting" patients; it is enforcing an information vacuum that only benefits entrenched incumbents with massive sales forces and decades-old patents.
Why the FDA Hates Bold Founders
Patrick Soon-Shiong is a polarizing figure. He’s brash, he’s wealthy, and he talks in "Moonshots." This makes him an easy target for a regulatory body that prefers the beige, risk-averse corporate speak of Pfizer or Novartis. The FDA's warning letter isn't just about Anktiva; it’s a shot across the bow for any founder who dares to market with the urgency that the cancer crisis demands.
We have reached a point where the "safety" of the marketing material is more scrutinized than the utility of the medicine. The FDA’s stance implies that doctors—individuals who spent twelve years in post-secondary education—are so fragile and easily misled that a press release will override their clinical judgment. It’s an insulting premise. It assumes the medical community is incapable of identifying a "bold claim" and demanding the underlying data.
The Cost of Regulatory Pedantry
What happens when the FDA creates a "gotcha" environment for biotech communications?
- Capital Flees to the "Safe" Bets: Investors stop funding radical innovations (like IL-15 superagonists) because the "regulatory risk" of the founder’s mouth is too high. They pour money into the 15th iteration of a PD-1 inhibitor instead.
- Information Asymmetry Increases: When companies are terrified to speak, the only information that circulates is through "independent" Medical Science Liaisons (MSLs) who are often just as biased but operate in the shadows where the FDA can’t see them.
- The "Innovation Tax" Spikes: Compliance departments now dwarf R&D teams. Every tweet, every slide deck, and every hallway conversation is filtered through three layers of legal counsel. This costs millions. Who do you think pays for that? The patient, in the form of a $15,000-per-month price tag.
Dismantling the "Misleading" Narrative
The FDA’s letter specifically called out the failure to include "prominent risk information." This is the oldest trick in the book. If a company doesn't spend 50% of its airtime listing "nausea, fatigue, and death," it’s labeled a bad actor.
Let’s be honest: in the context of oncology, risk is a given. We are talking about injecting synthetic proteins and modified viruses into human beings to kill mutated cells. The "risk" of not taking the drug is often death or permanent disability. By demanding that every communication be a funeral dirge of side effects, the FDA dilutes the signal of hope. It turns every medical breakthrough into a legal disclaimer.
The Industry’s Dirty Secret: We Like the Red Tape
The bitter irony is that "Big Pharma" loves these FDA crackdowns. Why? Because they have the infrastructure to navigate them. A multi-billion dollar conglomerate can afford a 200-person regulatory affairs team to ensure every comma is in the right place. A scrappy biotech trying to upend the status quo cannot.
The FDA’s "protection" is actually a moat. It protects the giants from the disruptors. By enforcing an archaic code of "balanced" communication that belongs in the 1950s, the agency ensures that only those with the deepest pockets can survive the gauntlet.
Stop Asking if it’s "Misleading" and Start Asking if it’s True
The press is asking: "Did Soon-Shiong lie?"
The FDA is asking: "Did he follow the formatting rules?"
The patient is asking: "Will this save my life?"
Only one of those questions matters. If the data shows that Anktiva provides a durable response in patients who have failed everything else, then the "misleading" nature of a press release is a rounding error in the grand scheme of human suffering.
We need to stop treating biotech founders like used car salesmen. When a founder is "heavily invested" or "emotionally charged," the media calls it a conflict of interest. I call it skin in the game. I’d rather bet on a billionaire who thinks his drug is a miracle than a faceless committee that views a 3% improvement in progression-free survival as a "successful fiscal quarter."
The Unconventional Path Forward
If you are an investor or a patient, ignore the FDA’s pearl-clutching. Look at the raw data in the New England Journal of Medicine or The Lancet. If the p-values are there, if the duration of response is meaningful, the adjectives don’t matter.
The next time you see a "Warning Letter" from the FDA, don't assume the drug is a fraud. Assume the company is finally saying something interesting enough to scare the bureaucrats. The status quo has a vested interest in keeping things quiet, professional, and slow. If we want to cure cancer, we need to get loud, unprofessional, and fast.
The FDA wants a world where every drug is described as "statistically significant but clinically modest." I’ll take the "misleading" breakthrough any day of the week.
Fire the copy editors. Hire more chemists. Stop apologizing for wanting to win.
